Department of Pulmonary Medicine, University of Tsukuba, Ibaraki, Japan.
Department of Respiratory Medicine, National Hospital Organization Ibaraki Higashi National Hospital, Ibaraki, Japan.
PLoS One. 2022 Mar 21;17(3):e0264397. doi: 10.1371/journal.pone.0264397. eCollection 2022.
Chronic inflammatory airway diseases, including asthma and chronic obstructive pulmonary disease (COPD), are complex syndromes with diverse clinical symptoms due to multiple pathophysiological conditions. In this study, using common and shared risk factors for the exacerbation of asthma and COPD, we sought to clarify the exacerbation-prone phenotypes beyond disease labels, and to specifically investigate the role of the IL4RA gene polymorphism, which is related to type 2 inflammation, in these exacerbation-prone phenotypes.
The study population comprised patients with asthma (n = 117), asthma-COPD overlap (ACO; n = 37) or COPD (n = 48) and a history of exacerbation within the previous year. Cluster analyses were performed using factors associated with both asthma and COPD exacerbation. The association of the IL4RA gene polymorphism rs8832 with each exacerbation-prone phenotype was evaluated by multinomial logistic analyses using non-asthma non-COPD healthy adults as controls (n = 1,529). In addition, the genetic influence of rs8832 was also examined in asthma patients with allergic rhinitis and no history of exacerbation (n = 130).
Two-step cluster analyses identified five clusters that did not necessarily correspond to the diagnostic disease labels. Cluster 1 was characterized by high eosinophil counts, cluster 2 was characterized by smokers with impaired lung function, cluster 3 was characterized by the presence of gastroesophageal reflux, cluster 4 was characterized by non-allergic females, and cluster 5 was characterized by allergic rhinitis and elevated total immunoglobulin E levels. A significant association with rs8832 was observed for cluster 5 (odds ratio, 3.88 (1.34-11.26), p = 0.013) and also for the type 2 exacerbation-prone phenotypes (clusters 1 and 5: odds ratio, 2.73 (1.45-5.15), p = 1.9 × 10-3).
Our results indicated that the clinical heterogeneity of disease exacerbation may reflect the presence of common exacerbation-prone endotypes across asthma and COPD, and may support the use of the treatable traits approach for the prevention of exacerbations in patients with chronic inflammatory airway diseases.
慢性炎症性气道疾病,包括哮喘和慢性阻塞性肺疾病(COPD),是具有多种临床表现的复杂综合征,这是由于多种病理生理条件造成的。在这项研究中,我们利用哮喘和 COPD 恶化的常见和共同危险因素,旨在阐明超越疾病标签的易恶化表型,并特别研究与 2 型炎症相关的 IL4RA 基因多态性在这些易恶化表型中的作用。
研究人群包括在过去一年中有过恶化史的哮喘患者(n=117)、哮喘-COPD 重叠(ACO;n=37)或 COPD 患者(n=48)。使用与哮喘和 COPD 恶化相关的因素进行聚类分析。使用非哮喘非 COPD 健康成年人作为对照(n=1529),通过多项逻辑回归分析评估 IL4RA 基因多态性 rs8832 与每种易恶化表型的相关性。此外,还在无恶化史的哮喘合并变应性鼻炎患者(n=130)中研究了 rs8832 的遗传影响。
两步聚类分析确定了五个不一定对应诊断疾病标签的聚类。聚类 1 的特征是嗜酸性粒细胞计数高,聚类 2 的特征是肺功能受损的吸烟者,聚类 3 的特征是存在胃食管反流,聚类 4 的特征是非过敏的女性,聚类 5 的特征是变应性鼻炎和总免疫球蛋白 E 水平升高。rs8832 与聚类 5 显著相关(比值比,3.88(1.34-11.26),p=0.013),也与 2 型易恶化表型(聚类 1 和 5:比值比,2.73(1.45-5.15),p=1.9×10-3)显著相关。
我们的结果表明,疾病恶化的临床异质性可能反映了哮喘和 COPD 中存在共同的易恶化表型,并且可能支持使用可治疗特征的方法来预防慢性炎症性气道疾病患者的恶化。